Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat

Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir

MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA

FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia

Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA

OSE Immunotherapeutics prioritises pouchitis and hidradenitis suppurativa for lusvertikimab development

WuXi Biologics collaborates with Sinorda Biomedicine for antibody development

Solvonis expands SVN-015 into depression following positive preclinical data

Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE

Glaukos receives FDA approval for repeat administration of iDose TR

Bio-Techne launches ultra-sensitive neurodegenerative disease assays on Ella platform

MedPal AI announces approval to supply Eli Lilly medicines in UK

Biophytis secures Asian partnership and investment to advance Phase 3 sarcopenia programme

Insilico Medicine agrees drug development collaboration with Qilu Pharmaceutical Group

HanchorBio partners with WuXi Biologics for development and manufacturing of next-gen bi- and multi-functional fusion programmes